Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
Method
Research works printed but not linked: 1
- Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. doi: 10.1126/science.aad0095. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Items 401–500 of 589
Jeibouei, S., Hojat, A., Mostafavi, E., Aref, A. R., Kalbasi, A., Niazi, V., Ajoudanian, M., Mohammadi, F., Saadati, F., Javadi, S. M. R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11023-z · Cited by 8
Self-citationA 3D tumor spheroid model with robust T cell infiltration for evaluating immune cell engagers
Lo, H. C., Choi, H., Kolahi, K. S., Rodriguez, S., Gonzalez, L., Chu, F., Shrotre, A., Zhao, X., D’Souza, A. L., Ferrando, R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112996 · Cited by 11
Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk
Buzhor, M. G., Longobardi, G., Kandli, O., Krinsky, A., Avramoff, O., Katyal, A., Salomon, K., Miari, A., Venkert, D., Barnatan, T. T., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503198 · Cited by 12
Song, F., Lu, Y.-J., Sun, H., Cheng, J.-W., Li, W., Liu, Z., Li, R., Wang, P.-X., Zheng, W.-J., Zhong, Y.-C., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014555 · Cited by 9
“8 9 15 While immunocompetent mouse models offer mechanistic insights, their translational relevance is hindered by interspecies differences in immune biology.”
Rodolfo, M., Huber, V., Cossa, M., Gallino, G., Leone, B. E., Vallacchi, V., Rivoltini, L., & Vergani, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068091 · Cited by 8
“Our results are in line with the numerous other investigators operating in the 3D cancer model field (15, 17, 20, 22, 24, 25) and we encourage the establishment in the clinics of personalized ex vivo platforms to test immunotherapy efficacy, define prediction markers and develop combination strategies.”
BackgroundMethodResultInfluentialWang, X., Tao, Y., Zhang, C., Tian, J., & Yu, W. (2024) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-023-00049-9 · Cited by 8
“Specifically, the TCGA dataset (sourced from GDAC Firehose) [37] was utilized for identification and analysis of co-expression genes associated with these cancers.”
Dey, S., Kinoshita, M., Puttick, S. G., Rose, S., Trau, M., Roberts, M. J., & Koo, K. M. (2024) · Advanced Sensor Research · doi:10.1002/adsr.202300193 · Cited by 9
Li, S., Shen, Y., Dong, C., Yin, S., Zhou, D., & Zhou, A. (2024) · Cell investigation. · doi:10.1016/j.clnves.2024.100005 · Cited by 9
Self-citationLeveraging Patient‐Derived Models for Immunotherapy Research
Politi, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280579 · Cited by 7
Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy
Liang, A., Tao, T., Chen, J., Yang, Y., Zhou, X., Zhu, X. M., & Yu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104716 · Cited by 6
Chang, C., Tsai, C.-C., Cheng, C., Chu, T.-Y., Chiang, C., Lee, Y., Wu, C., Chen, J., Kuo, C., & Hsu, P.-C. (2025) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_256_24 · Cited by 11
“3D microfluidic cultures replicate in vivo therapeutic sensitivity and can be used to study the underlying mechanisms of response and resistance to ICIs, develop novel combination therapies, and facilitate precise tumor immunotherapy [73].”
Self-citationAdvancements and challenges in culturing patient-derived cancer cells for personalized therapeutics
Fu, Y., Khoo, B. L., & Lim, C. T. (2025) · Frontiers in Lab on a Chip Technologies · doi:10.3389/frlct.2025.1663420 · Cited by 10
Modeling anti-tumor immune responses using patient-derived melanoma organoids
Kaminska, K. K., Phung, B., Karlström, J., Lauss, M., Harbst, K., Svensson, T., Pietras, K., Nielsen, K., Carneiro, A., Ekedahl, H., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04269-9 · Cited by 6
Mercadante, M., Scheben, A., Estrada, J., Savas-Carstens, J., Sullivan, W., Housel, N., Sapar, M. L., Volpari, T., Hebner, J., Rusielewicz, T., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01251-7 · Cited by 7
Ramasubramanian, T. S., Adstamongkonkul, P., Scribano, C. M., Johnson, C., Caenepeel, S. R., Hrycyniak, L., Vedder, L., Dana, N., Baltes, C., Browning, V. L., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07378-2 · Cited by 7
“Tumor fragment models derived from surgical resections also preserve the native TME and allow cytokine-based assessment of response [13, 16, 17].”
Patient-derived melanoma models
Karras, F., & Kunz, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155231 · Cited by 6
Eguren‐Santamaría, I., Rodríguez, I., Herrero, C., de Piérola, E. F., Azpilikueta, A., Sánchez‐Gregorio, S., Bolaños, E., Gomis, G., Molero-Glez, P., Chacón, E., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2373519 · Cited by 6
“4,38,39 In human samples, we observed remarkable levels of inter-and intra-patient heterogeneity, but importantly some levels of induction of IFNγ upon culture with the combination of nivo-lumab plus urelumab could be observed in a proportion of cases.”
BackgroundDinić, J., Stojanov, S. J., Dragoj, M., Grozdanić, M., Podolski-Renić, A., & Pešić, M. (2024) · Life · doi:10.3390/life14091142 · Cited by 12
“Second, they improve treatment outcomes by providing insight into how a patient’s tumor cells respond to different therapies, helping oncologists make more informed treatment recommendations.”
BackgroundZhang, Y., Li, Z., Ritter, J., Brea, E. J., Mahadevan, N. R., Dillon, D. A. R., Park, S.-R., Liu, E. M., Tolstorukov, M. Y., McGourty, W. E., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102198 · Cited by 13
Self-citationRamapriyan, R., Barker, F. G., Richardson, L. G., Sun, J., Vandecandelaere, G., Shim, J. M., Vlaminck, G. D., Gaffey, M., Grewal, E. P., Tazhibi, M., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf155 · Cited by 6
Self-citationHojat, A., Jeibouei, S., Aref, A. R., Kalbasi, A., Moghaddam, M., Mohammadi, F., Javadi, S. M. R., Ajoudanian, M., Sharifi, K., Zali, H., et al. (2021) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr.123828 · Cited by 6
“We used a microfluidic device, which was suitable for the culture of human-derived-tumor spheroids (15, 16, 21).”
MethodSelf-citationRole of IKKε in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology
Xiao, Q.-A., He, Q., Li, L., Song, Y., Chen, Y.-R., Zeng, J., & Xia, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.888588 · Cited by 8
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaPreprint
Nolan, G. P., Phillips, D. J., Matusiak, M., Rivero‐Gutiérrez, B., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-122285/v1 · Cited by 6
Sadegh, R. K., Saleki, K., & Rezaei, N. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114837 · Cited by 6
Gupta, R., Radhakrishnan, R. A., Kabekkodu, S. P., & Chakrabarty, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189504 · Cited by 6
Zheng, Y., Qian, C., Zhang, S.-Y., Wen, M.-C., Xu, X., Zhou, X., Wan, Y.-C., Zhang, L., & Cheng, W. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08312-6 · Cited by 5
“Additionally, conventional 3D spheroid models are unable to sustain the long-term functional in fi ltration and functional activity of immune cells [25, 26].”
Meng, Z., Niu, X., Xia, L., Chen, Y., Wang, Z., Wang, H., Ji, P., Cui, W., Wang, Y., & Lü, S. (2023) · Advanced Biology · doi:10.1002/adbi.202200264 · Cited by 7
Organoid Models in Cancer Immunotherapy: Bioengineering Approach for Personalized Treatment
Noorintan, S. T., Angelius, C., & Torizal, F. G. (2024) · Immuno · doi:10.3390/immuno4040020 · Cited by 6
“This approach addresses the challenge of resistance to PD-1 blockade and the need for biomarkers to guide treatment, facilitating therapeutic combination development and precision immuno-oncology efforts [57].”
Wang, Y., Chen, H., Zhang, Z., He, Y., Ji, L., Zhao, B., Wang, Q., Xu, J., Mao, S., Zhang, W., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122708 · Cited by 5
“In addition, microphysiological devices were constructed utilizing collagen hydrogels to investigate the influence of distinct immune cell populations on tumor cells [39,40].”
Goto, A., Moriya, Y., Nakayama, M., Iwasaki, S., & Yamamoto, S. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101003 · Cited by 5
Iñañez, A., Rey-Vergara, R. D., Quimis, F. G., Rocha, P., Galindo-Campos, M. A., Menéndez, S., Masfarré, L., Sánchez, I., Carpes, M., Martínez, C. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031293 · Cited by 5
Introduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges
Willers, H., & Eke, I. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_1 · Cited by 5
Baru, A., Sharma, S., Purakayastha, B. P. D., Khan, S. M., Mazumder, S., Gupta, R., Kundu, P. K., & Arora, N. M. (2021) · Assay and Drug Development Technologies · doi:10.1089/adt.2021.031 · Cited by 5
“45 Therefore, we first measured the percentage of PD-L1 and PD-1 expression in tumor tissueoids (MCF-7 and A-375) and T cells, respectively.”
Cultivating human tissues and organs over lab-on-a-chip models: Recent progress and applications
Bhagat, S., & Singh, S. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.07.023 · Cited by 5
de Nigris, F., Meo, C., & Palinski, W. (2023) · Cells · doi:10.3390/cells12172204 · Cited by 5
Amlexanox enhances the antitumor effect of anti-PD-1 antibody
Takeda, K., Yano, K., Yamada, K., & Kihara, A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.04.126 · Cited by 5
Helleday, T. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.007 · Cited by 5
Crosstalk and Prospects of TBK1 in Inflammation
Liu, H., Sheng, Q., Dan, J., & Xie, X. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2392587 · Cited by 5
“…the antitumor effects of TBK1 inhibitors in cancer (Alam et al., 2022; Runde et al., 2022), including MMB (Ng et al., 2019; Pardanani et al., 2009), Compound I (Jenkins et al., 2018), AZ909 (Posch et al., 2013; Vu & Aplin, 2014), Compound 3i (Crew et al., 2018), and UNC6587 (Hu et al., 2020).”
Self-citationHuman Melanoma Skin Cancer Models: A Step Towards Drug Testing & Target Therapy
Zarnaghi, B. B., Zarnaghi, E. B., Nilforoushzadeh, M. A., Roshanzamir, N., Amirkhani, M. A., & Sisakht, M. M. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10870-3 · Cited by 6
“Applying lymph node from the patients or using heterogeneous immune cell types are the solutions have been proposed to add enough immune compartments to the 3D melanoma models [47, 48].”
Heilala, M., Turpin, R., Pahimanolis, N., Nonappa, N., Ikkala, O. T., Klefström, J. T., & Munne, P. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c06549 · Cited by 4
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer
Hong, D., Lyu, Y., Nayak, R., Becker, J. S., Booker, M. A., Masuzawa, K., Devos, Z., Wang, T., Saito, S., Liu, Q., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.07.023 · Cited by 5
Self-citationBrea, E. J., Baldacci, S., Savage, N. J., Facchinetti, F., Hinchey, C., Chakravarti, S., Mottram, A., Ngo, K. H., Vo, H. V., Leeper, B. A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0527 · Cited by 6
“We previously established the use of primary organotypic tumor spheroids for assessing immune responses, including in xenograft-and patient-derived samples (31).”
Self-citationWu, Z., Zeng, B., Seah, D. H., Ng, I. Z. R., Ding, R. H., Zhang, T., Kalaichelvan, M., You, R., & Fong, E. L. S. (2025) · Advanced Materials · doi:10.1002/adma.202512252 · Cited by 5
Ni, D., Xing, J., Niu, G., Qiu, J., Wei, G., Chen, G., Zhou, Q., & Yin, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1757516 · Cited by 5
“Patient-Derived Organotypic Tumor Spheroids (PDOTS): This microfluidic-based method cultures small tumor fragments (40–100 μm in diameter) within a collagen matrix flanked by media channels (Jenkins et al., 2018).”
InfluentialGustafson, A. M., Bhasin, A., Gasmi, B., Bui, B. D., Ade, C. M., Hanada, K., Halas, H. K., Gartner, J. J., Prickett, T. D., Salazar, J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014644 · Cited by 5
“17 18 We have previously shown that PDTO can be used to identify neoantigen-specific T cells for adoptive cell transfer, 12 but there is a paucity of data assessing the correlation between clinical response and autologous organoid recognition by adoptively transferred neoantigen-specific TIL.”
Shetty, S., Kumar, N. A. N., Kabekkodu, S. P., & Chakrabarty, S. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189627 · Cited by 6
Preparation and analysis of monotypic and organotypic tumor spheroids
Domingues, A. C. M., Palin, C. A., Sun, Y., Xie, H., Woods, E. C., Jenkins, R. W., & Revach, O. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.11.003 · Cited by 4
Self-citationA Comprehensive Analysis of Epoxide Hydrolase 2 ( EPHX2 ) in Pan‐Cancer
Hu, W., Ding, X., Wu, X., Xi, X., Xu, J., Dai, S., Chen, J., Hu, S., Zhao, Q., & Chen, F. (2025) · Cancer Reports · doi:10.1002/cnr2.70188 · Cited by 8
“Cancer has become one of the leading causes of death worldwide and significantly affects quality of life [1, 2].”
Organoids: the new kid in cancer research
Narasimhan, V., Das, A., Pham, T. D., Wilson, K., Kong, J. C. H., Ramsay, R. G., & Heriot, A. G. (2019) · ANZ Journal of Surgery · doi:10.1111/ans.15256 · Cited by 5
“Organoids provide a valuable strategy to evaluate the response to immunotherapy in patients, thereby selecting those likely to respond to immunotherapy, and avoiding immunotherapy related complications in non-responders.(9) One of the most promising areas for the utilization of organoids is in drug development and per…”
BackgroundTo explore the mechanism of Yigong San anti-gastric cancer and immune regulation
Lu, D., Yuan, L., Wang, Z., Zhao, J.-J., Du, Y., Ning, N., Chen, G., Huang, S.-C., Yang, Y., Zhang, Z., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1965 · Cited by 7
Hu, Q., Zheng, Q., Du, X., Yang, Z., Tian, Q., Liang, L., Zhao, X., Bai, H., Liu, Y., Zhao, M., et al. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116960 · Cited by 4
Tumor-on-a-chip devices for cancer immunotherapy
Mu, X., & Zhang, Y. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00006-1 · Cited by 3
Xu, S., Xi, Y., Tang, L., Dai, G., & Luo, C. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6521953 · Cited by 5
“Furthermore, TBK1 signaling in both cancer and immune cells can promote immunosuppression, and potent/specific TBK1 inhibitors have been shown to potentiate ICI responsiveness in preclinical models [10, 30].”
BackgroundRetractedListening in on Multicellular Communication in Human Tissue Immunology
Albers, J. J., & Pelka, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884185 · Cited by 6
“Lastly, small-molecule screens in organoids (60), PDOTs (39), ALI-PDOs (40), or Organ-on-achip systems (41) can be used to identify candidates for targeted therapeutic interventions (60).”
BackgroundEs, H. A., Aref, A. R., & Warkiani, M. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2513-2_4 · Cited by 4
Self-citationKriplani, P. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892817666220804142633 · Cited by 4
Shao, S., Duncko, D., & Jones, C. N. (2025) · Lab on a Chip · doi:10.1039/d5lc00526d · Cited by 4
Meningioma microenvironment harbors a rich immune landscape that evolves with biological state
Guo, X., Moynihan, Z. A., Driver, J., Patel, R. V., Bhave, V. M., Maury, E. A., Knelson, E. H., Guo, H., Lin, J., Coy, S., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag022 · Cited by 3
Self-citationHwang, J., Ocampo, T. A., Mayer, V. W., Kang, J., Paranandi, K. S., Kim, Y. J., Han, Z., Cavaliere, J. P., Kudruk, S., Lorch, J. H., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3876 · Cited by 4
Self-citationWei, S., Deng, Y., Lee, J., Lan, H., Yang, Z., Labrie, M., Betts, C. B., Duan, H., Tate, B. J., Pucilowska, J., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102716 · Cited by 5
Self-citationB7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response
Arya, S., Ventin, M., Cattaneo, G., Nebbia, M., Sanatkar, S. A., Martin, C., Jia, J., 김방진, Bailey, C. A., Bardeesy, N. M., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03723-5 · Cited by 3
“To evaluate the viability of the PDOTS, we utilized a dual-label fluorescence live/dead staining method along with Hoechst dye (Sigma-Aldrich, 23,491–45-4) to label nuclei and Propidium Iodide (Invitrogen, bMS500PI) [38].”
InfluentialSkin Organoid Research Progress and Potential Applications
Li, H., Ren, K., Wang, C., & Bu, W.-B. (2021) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000201 · Cited by 5
Discovery of novel TANK-Binding Kinase 1 (TBK1) inhibitor against pancreatic ductal adenocarcinoma
Shih, W.-H., Huang, H.-L., HuangFu, W., Lin, T. E., Sung, T.-Y., Li, M., Huang, G., Chang, Y.-W., Yen, S., Hsieh, H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137296 · Cited by 4
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease
Bertuccio, F. R., Agustoni, F., Galli, G., Bortolotto, C., Saddi, J., Baietto, G., Baio, N., Montini, S., Putignano, P., D’Ambrosio, G., et al. (2023) · Cancers · doi:10.3390/cancers15245731 · Cited by 3
“Treating tissue fragment explants and patient-derived organotypic tumor spheroids (PDOTS) in short-term culture facilitates the development of immunological treatments as a result of advancements in the study of the human TIME using patient samples [111,112].”
Using 3-Dimensional Cultures to Propagate Genetically Modified Lung Organoids
Chen, F., Naughton, K. J., Lee, J., & Brainson, C. F. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3854-5_2 · Cited by 3
Li, R. M., Dong, Q., Jian, H., & Bai, S. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100030 · Cited by 5
Safaeifard, F., Goliaei, B., Aref, A. R., Foroughmand-Araabi, M.-H., Goliaei, S., Lorch, J. H., Jenkins, R. W., Barbie, D. A., Shariatpanahi, S. P., & Rüegg, C. (2022) · Cells · doi:10.3390/cells11223534 · Cited by 3
“Cell migration tracking: Patient-derived organotypic tumor spheroids were obtained as previously reported [42] and studied for the migration activity of immune cells in response to checkpoint blockade (Figure 1a).”
InfluentialSelf-citationA Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine
Şekeroğlu, Z. A., & Şekeroğlu, V. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096285910240206044830 · Cited by 3
Microfluidics for Immuno‐oncology
Ma, C., Harris, J., Morales, R. T., & Chen, W. (2019) · Wiley eBooks · doi:10.1002/9783527818341.ch5 · Cited by 5
Horowitz, L. F., Rodríguez‐Mias, R. A., Chan, M., Zhu, S., Tang, Y., Locke, A., Gottshall, N. R., Stepanov, I., Stiles, C., Yeung, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.22.586189 · Cited by 3
Costabile, F., George, S. S., Facciabene, A., Filaci, G., & Mastrogiacomo, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1572315 · Cited by 3
Protocol for the preparation and analysis of patient-derived organotypic tumor spheroids
Palin, C. A., Jenkins, R. W., & Revach, O.-Y. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.104286 · Cited by 2
“Examination of mixed tumor histology can be informative as a signal-finding endeavor, 7,8 but if biology is restricted to a given tumor type, a more uniform cohort may be more appropriate.”
Self-citationSirc, N., Smolander, J., Kumari, A. N., Liu, J., Lee, M. H., Lahdensuo, K., Järvinen, R., Tornberg, S., Lin, L., Laitinen, H. K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0447 · Cited by 3
“Patient-derived ex vivo culture systems have emerged to model treatment responses to immunotherapies (18, 35, 40–42).”
Rojas-Jiménez, E. A., Bui, T. M., Yan, P., Li, Z., Seehawer, M., Nishida, J., Foidart, P., Freeman, G. J., & Polyák, K. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501052123 · Cited by 3
“Increase in the expression of Irf1 , a master transcrip tion factor in the TNF -α via NF -κ B pathway induced by IFN -γ , was particularly prominent in luminal and LP - like tumor epithelial cells ( SI Appendix , Fig.”
InfluentialSelf-citationYu, Y., Li, Y., Wang, J., Zhu, Y.-J., Zhang, Z., Xiao, Z., Chen, Y., Qu, Y., Han, L., & Zhang, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00757-5 · Cited by 3
“Comprehensive analysis of cytokines secreted by PDOTS captured critical characteristics linked to both responsiveness and resistance to PD-1 blockade, illustrating that PDOTS-based profiling serves as an innovative platform for assessing ICB using clinically relevant patient specimens [32].”
InfluentialSelf-citationChen, Y., Xu, N. L. J., Dong, M., Liu, W., Liu, Z., Sun, G., & Jia, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773734 · Cited by 2
“Tissue fragments are loaded into microchannels and interact with epithelial, stromal, and immune cells under physiological fl ow conditions (44).”
Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression
Liao, C., Lyu, S., Johnson, R. L., Shang, T., Wang, X., Gildor, N., Li, S., Williams, N. S., James, L. I., Hu, L., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.03.013 · Cited by 3
Self-citationLee, J. B., Baek, S., Kim, D. K., Kwon, B.-E., Ahn, J. S., Nagasaka, M., Davar, D., Park, H., Kim, H. G., Im, J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014702 · Cited by 3
Self-citationIzadpanah, R., Izadpanah, A., & Alt, E. U. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108304 · Cited by 2
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
Braun, D. A., Dana, N., Hernan, H. R., Sahni, S., Scribano, C. M., Johnson, C., Vedder, L., von Euw, E., Zweng, J., Wargowski, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103114 · Cited by 2
Graves, A. C., Mukherjee, A., Yang, R. Y., Mordant, A. L., Webb, T., Bryant, K. L., Herring, L. E., & Baldwin, A. S. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110535 · Cited by 2
Novobrantseva, T. I., Manfra, D. J., Ritter, J., Razlog, M., O’Nuallain, B., Zafari, M. R., Nowakowska, D., Basinski, S., Phennicie, R., Nguyen, P. A., et al. (2024) · Cancers · doi:10.3390/cancers16162778 · Cited by 2
“It has been established that a response of at least 30% induction of a single key cytokine (e.g., IFNg) in the ex vivo tumor model is correlative with clinical responses [33,34].”
BackgroundEl-Derby, A. M., Schaaf, C. R., Shelkey, E., Cook, K. L., Votanopoulos, K. I., & Söker, S. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1411322 · Cited by 2
“These tumor immune organoids were fabricated by encapsulating the tumor and immune cells in a modified collagen based hydrogel (Shelkey et al., 2021).”
InfluentialClinical Applications, Patents, and Challenges in Cancer Immunotherapy
Nanda, A., Kanhar, S., Singh, M. K., Akram, W., & Haider, T. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_18 · Cited by 2
In vivo imaging of inflammatory response in cancer research
Konishi, Y., & Terai, K. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00261-x · Cited by 2
“Despite the recent advancement of organoid culture systems for modeling the tumor microenvironment [6, 7], recapitulation of inflammatory responses in vitro has yet to be achieved.”
BackgroundTargeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLCPreprint
Ao, L., Jia, W., Gong, Q., Cui, J., Wang, J., Yu, Y., Fu, C., Li, H., Wei, J., Wang, R. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.01.582888 · Cited by 3
Wei, S. N., Du, K., Lan, H., Yang, Z., Deng, Y., Wei, Z., Frederick, D. T., Lee, J., Labrie, M., Tian, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.12.612675 · Cited by 3
Self-citationFilippova, S. Y., Тимофеева, С. В., Межевова, И. В., Shalashnaya, E. V., Rozenko, L. Y., Av, S., & Novikova, I. A. (2023) · Russian Journal of Oncology · doi:10.17816/onco516562 · Cited by 1
Khan, F., Liu, Y., Whitfield, D., Pang, L., Ali, H. A., Huang, Y., Zhou, F., Hagan, R. S., Frenis, K., Rowe, R. G., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2420793122 · Cited by 3
“…whether TBK1 - regulated TAMs contribute to EMT, we examined the expression of EMT - related markers in breast cancer cells upon communicating with TAMs in the presence or absence of TBK1 inhibitor, BX795 hydrochloride (BX795) (31, 32), compound 1 (CMPD - 1) (33), or amlexanox (Amlex) (34) (Fig.”
RetractedBeyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing
Chan, M., & Gujral, T. S. (2025) · Oncogene · doi:10.1038/s41388-025-03637-0 · Cited by 1
“…Alsaed et al. used patient-derived lung cancer organoids co-cultured with patient-matched peripheral blood mononuclear cells (PBMCs) to create an ex vivo tumor-on-chip (TOC) platform that can be used to assess ef fi cacy of ICB in lung cancer models by using cell viability as a readout [25, 39].”
Ye, Y., Srisai, D., & Barsky, S. H. (2025) · Biomedicines · doi:10.3390/biomedicines13122890 · Cited by 1
Heras, U., Pardo-Sánchez, J. M., Fallert, L., de Aberasturi, D. J., Mitxelena‐Iribarren, O., & Cipitria, A. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070824-124153 · Cited by 2
Huang, C., Zhao, S., Wu, Z., Zhu, Q., Zhou, K., Wang, M., Li, R., Cai, B., Zou, D., Liu, W., et al. (2026) · Journal of Analysis and Testing · doi:10.1007/s41664-026-00423-z · Cited by 1
Zirnbauer, R., Ammon, D., Mosleh, B., Speiser, N., Theophil, A., Fabits, M., Hoda, M. A. R., Bergmann, M. M., & Laengle, J. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03707-5 · Cited by 1
Engineering Organ-on-a-Chip Systems for Cancer Immunotherapy: Strategies and Assay Integration
Wang, J., & Wang, Z. (2026) · Bioengineering · doi:10.3390/bioengineering13050492 · Cited by 1
Skin organoid diversity and applications in biomedical research: A comprehensive review
Liang, L., Zhou, J., & Leng, L. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100492 · Cited by 3
Liu, W.-W., Xie, X.-S., & Yang, X.-J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08278-9 · Cited by 3
“Robust clinical validation—ideally through prospective, blinded studies coupled with multi-omics readouts—will likely be required before these platforms can be routinely used for treatment stratification [99, 100, 118].”
Wang, F., Zhu, L.-L., Ji, C., Deng, J., Han, L., Song, F., & Chen, Z. X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744326 · Cited by 1
Self-citationMicrofluidic platforms for preclinical evaluation of immunotherapies
Massaro, A., Blackledge, C. W., & Shelton, S. E. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115918 · Cited by 1
Ko, Y. R., Park, C. W., Kim, J., Jung, D. J., Kim, S. M., Park, H. S., Ahn, B., Hwang, H. S., Sung, C. O., & Jang, S. J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08487-2 · Cited by 1
“…to reproducibly reconstitute individualized TMEs ex vivo, demonstrated here in both immunologically active and cold tumors, provides a physiologically relevant framework for dissecting tumor-immune-stroma interactions and supports functional assessment of therapy-induced changes in situ [66, 67].”
Self-citation
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.